Brodalumab-Induced Eczematous Reactions in Psoriasis Patients: Management With Switching to Risankizumab.

Abstract

Biological treatments targeting IL-17 are highly efficacious with rapid onset of action in psoriasis. Cutaneous adverse events are associated with different biological treatments, including paradoxical psoriasis and eczematous reactions. Brodalumab was previously suggested as an alternative treatment option in psoriasis patients who developed dermatitis or paradoxical psoriasis while on a biologic. Here we report three psoriasis patients who developed brodalumab induced eczematous reaction with complete clearance after switching to risankizumab. Early recognition is crucial for appropriate management. We propose switching patients with psoriasis who develop severe eczematous reaction while on a biologic targeting IL-17 to an IL 23 inhibitor due to efficacy in psoriasis and rarely reported eczematous reaction.

• Authors: Adel Alsenaid, Vincent Piguet, Perla Lansang, Yvette Miller-Monthrope, Jensen Yeung, Marissa Joseph
• Journal: Journal of cutaneous medicine and surgery (J Cutan Med Surg) 2023 May-Jun Vol. 27 Issue 3 Pg. 236-240 ISSN: 1615-7109 [Electronic] United States
• PMID: 37014149 (Publication Type: Journal Article)

Chemical References

• risankizumab
• brodalumab
• Interleukin-17
• Biological Products

Topics

• Humans
• Interleukin-17
• Psoriasis (drug therapy)
• Eczema (chemically induced, drug therapy)
• Biological Products
• Treatment Outcome
• Severity of Illness Index